Interview: LSE stakes claim as source of patient capital for biotechs

Biotech and medtech companies looking to tap into the deep pools of US capital should consider a London listing. London Stock Exchange's Chris Mayo tells Mike Ward, global director of content for Informa's pharma insights products, that non-US companies can get access to US investors while not having to endure expensive reporting requirements. Moreover, he says, as many US biotechs and medtech businesses have listed in London as UK firms have listed in the US as they sought to attract what Mayo describes as patient capital.